Advances in cancer drug targets. Volume 3 / Atta-ur-Rahman, editor ; contributors Alain J. P. Alix [and thirty seven others].

Format:

Book

Contributor:

Rahman, Atta-ur-, editor.

Alix, Alain J. P., contributor.

Series:

Advances in Cancer Drug Targets

Advances in Cancer Drug Targets, 2213-9915 ; Volume 3

Language:

English

Subjects (All):

Cancer--Chemotherapy.

Cancer.

Drug targeting.

Drug delivery systems.

Physical Description:

1 online resource (278 p.)

Place of Publication:

Sharjah, United Arab Emirates : Bentham Science Publishers, 2016.

Summary:

Advances in Cancer Drug Targets is an e-book series that brings together recent expert reviews published on the subject with a focus on strategies for synthesizing and isolating organic compounds and elucidating the structure and nature of DNA. The reviews presented in this series are written by experts in pharmaceutical sciences and molecular biology. These reviews have been carefully selected to present development of new approaches to anti-cancer therapy and anti-cancer drug development. The contents of this volume include reviews on mediating or inhibiting different signaling pathways such as WNT signaling and MTOR as well as novel drug targets for tumor control such as neutrophil elastase and estrogen sulfatase. These reviews provide updates on new ways to treat a variety of cancers. The reference work serves to give readers a brief yet comprehensive glance at current theory and practice behind employing chemical compounds for tackling tumor suppression, DNA site specific drug targeting and the inhibition of enzymes involved in growth control pathways. This e-book volume will be of special interest to molecular biologists and pharmaceutical scientists.

Contents:

CONTENTS; PREFACE ; List of Contributors ; Neutrophil Elastase as a Target in Lung Cancer: the State of the Art ; 1. INTRODUCTION: NEUTROPHIL ELASTASE/Α-1ANTITRYPSIN IMBALANCE AS A LINK BETWEEN CHRONIC OBSTRUCTIVE PULMONARY DISEASE AND LUNG CANCER; 2. MULTIFACETED FUNCTIONS OF NEUTROPHIL ELASTASE IN LUNG CANCER; 3. ENDEGNENOUS NEUTROPHIL ELASTASE INHIBITORS; 3.1. Proteinaceous Inhibitors; 3.2. Natural Compounds; 3.2.1. Glycosaminoglycans; 3.2.2. Phenolics; 3.2.3. Triterpenoids ; 3.2.4. Fatty Acids and Peptide Derivatives; 4. DESIGN OF DUAL NEUTROPHIL ELASTASE / MMP INHIBITORS

DESIGN OF DUAL HNE-MMP INHIBITORSCONCLUDING REMARKS; ADDITIONAL MATERIAL; 1. Molecular Modeling and Molecular Graphics; 2. Ligand and Receptor Preparation; 3. Docking Protocol; CONFLICT OF INTEREST; DISCLOSURE; ACKNOWLEDGEMENTS; ABBREVIATIONS; REFERENCES; Inhibition of Membrane Complement Inhibitor Expression (CD46, CD55, CD59) by siRNA Sensitizes Tumor Cells to Complement Attack ; INTRODUCTION; MATERIALS AND METHODS; Cell Culture; SiRNA Sequences; SiRNA Transfection; Flow Cytometry; Complement-mediated Cytotoxicity Assay (CDC); C3-binding Studies; Real-Time RT-PCR; Statistical Analysis

RESULTSDesign of siRNAs Specific for CD46, CD55 and CD59; SiRNA-mediated Downregulation of mCRP Expression; siRNA-mediated Augmentation of Tumor Cell Complement Lysis and Opsonization; Time-course of siRNA-induced mCRP Inhibition; Stable Downregulation of CD59 Using an Hairpin siRNA Expression Vector; DISCUSSION; CONFLICT OF INTEREST; DISCLOSURE; ACKNOWLEDGEMENT; ABBREVIATIONS; REFERENCES; Points of Therapeutic Intervention along the Wnt Signaling Pathway in Hepatocellular Carcinoma ; INTRODUCTION; THE WNT SIGNALING PATHWAY; Overview of the Wnt Signaling; The Wnt/β-catenin Pathway

Aberrant Activation of the Wnt/β-catenin Pathway in HCCTARGETING THE WNT/Β-CATENIN PATHWAY IN HCC; Targeting the Upstream Components; Endogenous Inhibitors of the Ligand/Receptor Complex; Targeting Wnt Ligands and FZD Receptors ; Targeting the Dishevelled Protein; Cellular Trafficking and Targets; Targeting the β-catenin Destruction Complex; Targeting the β-catenin/TCF Transcriptional Complex; Pitfalls in Targeting the Wnt/β-catenin Pathway; CONCLUSIONS AND PERSPECTIVES ; CONFLICT OF INTEREST; DISCLOSURE; ACKNOWLEDGMENT; ABBREVIATIONS; REFERENCES

Collaboration of Epithelial Mesenchymal Transition and Cancer Stem Cells: Sinister Routes for Chemoresistant Recurrent Ovarian Cancer INTRODUCTION; PATHOLOGY OF OVARIAN CANCER; TRANSITION FROM EPITHELIAL TO MESENCHYMAL PHENOTYPE AND THE PROGRESSION OF CANCER ; EVIDENCE OF EMT IN OVARIAN CANCER; STEM CELLS IN NORMAL OVARIES AND OVARIAN CANCER; SPHERE FORMATION AND THE CANCER STEM CELL PHENOTYPE OF THE OVARY; ASSOCIATION OF EMT AND CSCS: A MERGER FOR POTENTIAL CHEMORESISTANCE IN OVARIAN CANCER

Cisplatin Induced EMT Generates Ovarian Cancer Stem-Like Cells: A Study on the OVCA 433 Cell Line as an Experimental Model

Notes:

Description based upon print version of record.

Includes bibliographical references at the end of each chapters and index.

Description based on online resource; title from PDF title page (ebrary, viewed May 3, 2016).

ISBN:

9781681082332

1681082330